quetiapine-fumarate and Tourette-Syndrome

This paper reviews the clinical pharmacology, efficacy and safety of the new atypical antipsychotic, ziprasidone. All published citations regarding ziprasidone were retrieved and reviewed using a MEDLINE search (completed for citations to early 2001). In addition, abstracts from recent scientific meetings presenting data not yet published were reviewed. Like other new antipsychotic medications, ziprasidone fits the profile of an atypical agent, exerting efficacy in positive and negative symptoms of psychosis, as well as affective symptoms, with a low risk of neurological and neuroendocrinological side effects. Unlike newer agents, it does not appear to be associated with weight gain in most patients.

Topics: Antipsychotic Agents; Benzodiazepines; Clinical Trials as Topic; Dibenzothiazepines; Dopamine Antagonists; Drug Interactions; Guidelines as Topic; Humans; Olanzapine; Piperazines; Pirenzepine; Quetiapine Fumarate; Risperidone; Schizophrenia; Serotonin Antagonists; Thiazoles; Time Factors; Tourette Syndrome

Topics: Adult; Antipsychotic Agents; Dibenzothiazepines; Humans; Male; Middle Aged; Quetiapine Fumarate; Tourette Syndrome; Treatment Outcome

The purpose of this study was to investigate the short-term safety and effectiveness of quetiapine in the treatment of children and adolescents with Tourette's disorder.. This was an 8-week, open-label trial that included 12 subjects with a mean age of 11.4 +/- 2.4 years. The subjects were seen every week throughout the study.. Clinical responses, as measured by the Turkish version of the Yale Global Tic Severity Scale, revealed a statistically significant reduction in tic scores ranging from 30-100%. Mean dose of quetiapine at the end of the study was 72.9 +/- 22.5 mg/day. Three subjects complained of sedation in the first week of treatment.. The favorable results of this open-label study should be interpreted with caution due to the uncontrolled nature of the study. Spontaneous waxing and waning of symptoms should also be considered. Further controlled studies are required.

Topics: Adolescent; Antipsychotic Agents; Child; Dibenzothiazepines; Dose-Response Relationship, Drug; Female; Humans; Male; Neuropsychological Tests; Psychiatric Status Rating Scales; Quetiapine Fumarate; Tourette Syndrome

Topics: Adolescent; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Autism Spectrum Disorder; Delusions; Dystonia; Female; Hallucinations; Humans; Hypnotics and Sedatives; Intellectual Disability; Lorazepam; Loxapine; Olanzapine; Paranoid Disorders; Psychotic Disorders; Quetiapine Fumarate; Tourette Syndrome

Topics: Adolescent; Antipsychotic Agents; Clozapine; Drug Therapy, Combination; Humans; Male; Quetiapine Fumarate; Receptors, Dopamine D4; Tourette Syndrome; Treatment Outcome

Topics: Adolescent; Antipsychotic Agents; Child; Dibenzothiazepines; Female; Humans; Male; Quetiapine Fumarate; Tourette Syndrome

The term Tourettism refers to Tourette Syndrome (TS)-like symptoms which appear secondary to a variety of both acquired and congenital neurological and neuropsychiatric disorders or following an exposure to several drugs. The association between Tourettism and Multiple Sclerosis (MS) is very rare. Only two cases of patients affected by MS who also showed a simple phonic tic and complex vocal tics respectively have been reported. The case here described reports of a 30 year-old woman affected by secondary-progressive MS who developed, 7 years after the onset of the disease, TS-like symptoms which were responsive to quetiapine. At that time her brain MRI, when compared with the previous scan, showed an increased lesion burden and an increased atrophy in the regions around Sylvian fissures. Considering recent findings on TS, the increased atrophy in these strategic brain regions could be responsible for the tics onset in our patient. At the same time, the diffuse involvement of the white matter and the progressive brain atrophy which we observed could have impaired the cortico-striato-thalamo-cortical circuits consistently implicated in the pathogenesis of TS. In conclusion, we can hypothesize that in our case Tourettism and MS could be considered causal related more than coincidentally associated.

Topics: Adult; Antipsychotic Agents; Atrophy; Basal Ganglia; Brain; Cerebral Cortex; Dibenzothiazepines; Disease Progression; Female; Humans; Magnetic Resonance Imaging; Multiple Sclerosis; Nerve Fibers, Myelinated; Neural Pathways; Quetiapine Fumarate; Thalamus; Tourette Syndrome; Treatment Outcome

Tourette's syndrome is a relatively common biological genetic disorder with a broad spectrum of neurobehavioural manifestations. Unfortunately, treatment of the condition is often unsatisfactory and all available drugs are associated with potential adverse effects. We therefore aimed to investigate the efficacy of quetiapine, a newer atypical antipsychotic, in the treatment of children and adolescents with Tourette's syndrome.. This was a retrospective study carried out in outpatient clinics. Twelve patients aged 8-18 years with Tourette's syndrome (diagnosed according to Diagnostic and Statistical Manual IV criteria) who were receiving quetiapine therapy and had no diagnosis of epilepsy, major depression or psychotic disorder, were included in the study. The main outcome measure was the Yale Global Tic Severity Scale (YGTSS) score.. The initial dose of quetiapine was 25 mg/day, but the mean dose was increased to 114.6 +/- 51.6 mg/day and 175.0 +/- 116.8 mg/day at the fourth and eighth weeks of treatment, respectively. The YGTSS score, which was 21.6 +/- 4.0 at baseline, showed significant decreases at 4 and 8 weeks (reducing to 7.5 +/- 7.4 and 5.6 +/- 8.1, respectively; p < 0.003). Routine laboratory parameters and serum prolactin level were all normal and did not change throughout treatment. Mild but significant increases in both bodyweight and body mass index at 4 and 8 weeks compared with baseline were observed.. Other than causing mild weight gain, quetiapine appears to be an effective, safe and well tolerated drug in children and adolescents with Tourette's syndrome.

Topics: Adolescent; Antipsychotic Agents; Child; Dibenzothiazepines; Female; Humans; Male; Quetiapine Fumarate; Severity of Illness Index; Tourette Syndrome; Treatment Outcome; Weight Gain

In this article we describe the clinical response of an 8-year-old boy with the Gilles de la Tourette syndrome (GTS) when treated with quetiapine. Upon admission for observation he received a trial course of quetiapine, to which he responded favourably. We searched the Medline and Psycinfo databases for information about the recommended dose of quetiapine for children with GTS. From the 12 case-studies and one open-label trial that we found, we conclude that the maximum dose of quetiapine for children with GTS is 200 mg. Data concerning the safety of quetiapine when administered to children are limited and contradictory.

Topics: Antipsychotic Agents; Child; Dibenzothiazepines; Humans; Male; Quetiapine Fumarate; Safety; Tourette Syndrome; Treatment Outcome

Topics: Aggression; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Child, Preschool; Dibenzothiazepines; Dose-Response Relationship, Drug; Humans; Male; Obsessive-Compulsive Disorder; Quetiapine Fumarate; Tourette Syndrome

A young man with a 13 year history of Tourette disorder and obsessive-compulsive disorder developed mania on clomipramine. Quetiapine 600 mg, daily was followed by resolution of the mania and improvement of the symptoms of Tourette disorder and obsessive compulsive disorder. It seems that quetiapine may be useful in treatment of Tourette disorder with or without comorbid disorders.

Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Clomipramine; Dibenzothiazepines; Humans; Male; Obsessive-Compulsive Disorder; Quetiapine Fumarate; Selective Serotonin Reuptake Inhibitors; Tourette Syndrome

Topics: Adolescent; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Child; Dibenzothiazepines; Humans; Male; Quetiapine Fumarate; Tic Disorders; Tourette Syndrome

Topics: Antipsychotic Agents; Child; Dibenzothiazepines; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Neurologic Examination; Quetiapine Fumarate; Tourette Syndrome; Treatment Outcome

Topics: Administration, Oral; Antipsychotic Agents; Child; Dibenzothiazepines; Humans; Quetiapine Fumarate; Tourette Syndrome; Treatment Outcome

Two children with Tourette's syndrome and comorbid disorders were treated with quetiapine, an atypical antipsychotic successfully used in patients with psychoses and schizophrenia with low incidence of extrapyramidal side effects. Clinical observations and standardized rating scales suggested that this drug produced beneficial effects on tics and other symptoms. Adverse effects (at low doses) were minimal. Because it was suggested that tic efficacy of the newer antipsychotics was related to higher D2 occupancy (with the exception of quetiapine and clozapine, which have relatively low D2 activity), it is hypothesized that tic patients are D2 sensitive and need lower doses of medications. These children were treated naturalistically and were reported retrospectively because of their encouraging outcomes. However, these findings should be interpreted with caution, because no contrast groups, drug withdrawal, or placebo were utilized. Controlled studies are needed to determine the efficacy of quetiapine in the treatment of Tourette's syndrome.

Topics: Adolescent; Antipsychotic Agents; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Basal Ganglia Diseases; Depressive Disorder; Dibenzothiazepines; Dyskinesia, Drug-Induced; Humans; Male; Psychiatric Status Rating Scales; Quetiapine Fumarate; Tourette Syndrome